World's Best Scientists 2026 revealed!
Award Badge
Medicine
Spain
2023

D-Index & Metrics

Medicine

D-Index
98
Citations
44593
World Ranking
8804
National Ranking
125

Juan J. Gomez-Reino publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Juan J. Gomez-Reino sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 610 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 445 publications — 48th percentile

48% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Juan J. Gomez-Reino D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Juan J. Gomez-Reino sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 399 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 98 D-Index — 57th percentile

57% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Research.com Recognitions

  • 2023 - Research.com Medicine in Spain Leader Award

Overview

Juan J. Gomez-Reino is affiliated with the University of Santiago de Compostela in Spain and specializes in Medicine with a focus on Rheumatology.

Their research covers multiple subfields including Rheumatology, Immunology, Hematology, Genetics, and Pathology and Forensic Medicine. The main topics studied are:

  • Rheumatoid Arthritis Research and Therapies
  • Autoimmune and Inflammatory Disorders Research
  • Spondyloarthritis Studies and Treatments
  • Systemic Lupus Erythematosus Research
  • Biosimilars and Bioanalytical Methods
  • Chronic Lymphocytic Leukemia Research
  • Psoriasis: Treatment and Pathogenesis

Their publication record includes numerous papers in various scientific venues, with frequent contributions to the following journals:

  • Annals of the Rheumatic Diseases
  • ACR Open Rheumatology
  • Seminars in Arthritis and Rheumatism
  • RMD Open
  • Patient Preference and Adherence

Among recent research outputs are the following publications:

  • Malignancy risk with tofacitinib versus TNF inhibitors in rheumatoid arthritis: results from the open-label, randomised controlled ORAL Surveillance trial, 2022, Annals of the Rheumatic Diseases
  • Clinical features and outcomes of COVID-19 in patients with rheumatic diseases treated with biological and synthetic targeted therapies, 2020, Annals of the Rheumatic Diseases
  • After JAK inhibitor failure: to cycle or to switch, that is the question - data from the JAK-pot collaboration of registries, 2022, Annals of the Rheumatic Diseases
  • Impact of baseline body mass index on the efficacy and safety of tofacitinib in patients with psoriatic arthritis, 2021, RMD Open
  • Adherence to Treatment in Patients with Rheumatoid Arthritis from Spain, 2021, Patient Preference and Adherence

Frequent coauthors in their research collaborations include:

  • Carlos Sánchez-Piedra
  • Manuel Pombo-Suárez
  • Federico Díaz-González
  • Jon T. Giles
  • Alexis Ogdie

Best Publications

  • Treating rheumatoid arthritis to target: recommendations of an international task force

    Josef S. Smolen;Daniel Aletaha;Johannes W J W Bijlsma;Ferdinand C Breedveld

  • EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs

    Josef S. Smolen;Robert Landewé;Ferdinand C Breedveld;Maxime Dougados

  • American College of Rheumatology/European League Against Rheumatism Provisional Definition of Remission in Rheumatoid Arthritis for Clinical Trials

    David T. Felson;David T. Felson;Josef S. Smolen;George Wells;Bi Zhang

  • Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force

    Josef S Smolen;Ferdinand C Breedveld;Gerd R Burmester;Vivian Bykerk

  • Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: A multicenter active-surveillance report

    Juan J. Gómez-Reino;Loreto Carmona;Vicente Rodríguez Valverde;Emilio Martín Mola

  • Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study.

    Mark C. Genovese;James D. McKay;Evgeny L. Nasonov;Eduardo F. Mysler

  • Effects of AIN457, a Fully Human Antibody to Interleukin-17A, on Psoriasis, Rheumatoid Arthritis, and Uveitis

    Wolfgang Hueber;Dhavalkumar D. Patel;Thaddeus Dryja;Andrew M. Wright

  • Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: The AMBITION study

    Graeme Jones;Anthony Sebba;Jieruo Gu;Mitchell B Lowenstein

  • Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study.

    Arthur Kavanaugh;Iain McInnes;Philip Mease;Gerald G. Krueger

  • Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists.

    Loreto Carmona;Juan J. Gómez-Reino;Vicente Rodríguez-Valverde;Dolores Montero

  • Adipokines as emerging mediators of immune response and inflammation

    Francisca Lago;Carlos Dieguez;Juan Gómez-Reino;Oreste Gualillo

  • Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations.

    D. Aletaha;R.B. Landewe;T. Karonitsch;J. Bathon

  • Changes in plasma levels of fat-derived hormones adiponectin, leptin, resistin and visfatin in patients with rheumatoid arthritis

    Miguel Otero;Rocio Lago;Rodolfo Gomez;Francisca Lago

  • The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement

    I. Solovic;M. Sester;J. J. Gomez-Reino;H. L. Rieder

  • Leptin, from fat to inflammation: old questions and new insights

    Miguel Otero;Rocı́o Lago;Francisca Lago;Felipe F. Casanueva

  • EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs

    J. S. Smolen;R. Landewé;F. C. Breedveld;M. Dougados

  • Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor

    Arthur F Kavanaugh;Philip J Mease;Juan Jesus Gomez-Reino;Adewale O Adebajo

  • Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection.

    Juan J Gómez-Reino;Loreto Carmona;Miguel Angel Descalzo

  • The emerging role of adipokines as mediators of inflammation and immune responses

    Francisca Lago;Carlos Dieguez;Juan Gómez-Reino;Oreste Gualillo

  • Leptin in the interplay of inflammation, metabolism and immune system disorders

    Vanessa Abella;Morena Scotece;Javier Conde;Jesús Pino

Frequent Co-Authors

Antonio Gonzalez
Antonio Gonzalez University of Santiago de Compostela
Oreste Gualillo
Oreste Gualillo Servicio Gallego de Salud
Loreto Carmona
Loreto Carmona Instituto de Salud Musculoesquelética
Francisco J. Blanco
Francisco J. Blanco University of A Coruña
John Loughlin
John Loughlin Newcastle University
Josef S. Smolen
Josef S. Smolen Medical University of Vienna
Alejandro Balsa
Alejandro Balsa Hospital Universitario La Paz
Tore K. Kvien
Tore K. Kvien University of Oslo
Paul Emery
Paul Emery University of Leeds
Andrew Carr
Andrew Carr University of Oxford

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those interested in pursuing careers in healthcare, there are several flexible online degree options to consider. Online nursing programs, in particular, have become increasingly popular for their accessibility and accelerated pathways.

If you are already a registered nurse seeking to advance your qualifications, online rn to bsn programs without clinical requirements offer an efficient route to earning your BSN without added clinical hours, making them ideal for busy professionals. Those looking to further their education and leadership in nursing can explore advanced options like dnp online programs and investigate the easiest dnp programs for a streamlined path to a Doctor of Nursing Practice degree.

Aspiring nurses just starting their journey may want to consider fast-paced entry-level options, such as an lpn fast track program that can quickly lead to licensure and employment. Exploring these varied online degrees can open many rewarding career pathways in healthcare.

Best Scientists Citing Juan J. Gomez-Reino

Trending Scientists

Recently Published Articles